Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) have received an average rating of “Hold” from the nine brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $5.00.

ACRX has been the subject of several research analyst reports. Royal Bank Of Canada set a $6.00 price objective on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of AcelRx Pharmaceuticals in a research report on Tuesday, October 3rd. Stifel Nicolaus upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Roth Capital set a $13.00 price objective on shares of AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Finally, ValuEngine cut shares of AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 15th.

AcelRx Pharmaceuticals (NASDAQ ACRX) traded up $0.02 during trading hours on Friday, hitting $1.97. 949,900 shares of the stock were exchanged, compared to its average volume of 1,697,173. AcelRx Pharmaceuticals has a 52 week low of $1.55 and a 52 week high of $5.75. The company has a debt-to-equity ratio of -0.47, a current ratio of 4.92 and a quick ratio of 4.81.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/12/acelrx-pharmaceuticals-inc-acrx-given-average-rating-of-hold-by-analysts.html.

In other news, insider Pamela P. Palmer bought 10,000 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The shares were bought at an average cost of $2.95 per share, with a total value of $29,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Lawrence G. Hamel sold 10,161 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $5.29, for a total transaction of $53,751.69. Following the completion of the sale, the insider now directly owns 16,379 shares in the company, valued at $86,644.91. The disclosure for this sale can be found here. Insiders have acquired a total of 37,000 shares of company stock worth $112,280 over the last three months. Insiders own 28.10% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. acquired a new position in AcelRx Pharmaceuticals in the 2nd quarter valued at about $530,000. WealthTrust Axiom LLC grew its stake in AcelRx Pharmaceuticals by 50.0% in the 2nd quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after buying an additional 70,000 shares during the last quarter. LMR Partners LLP acquired a new position in AcelRx Pharmaceuticals in the 2nd quarter valued at about $319,000. Virtu KCG Holdings LLC grew its position in shares of AcelRx Pharmaceuticals by 600.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after purchasing an additional 101,742 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of AcelRx Pharmaceuticals by 6.6% during the 1st quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock worth $355,000 after purchasing an additional 6,942 shares in the last quarter. Institutional investors and hedge funds own 23.52% of the company’s stock.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.